|Mr. Alfred F. Altomari||Chairman & CEO||894.05k||N/A||1959|
|Mr. Dennis P. Reilly||Sr. VP & CFO||550.76k||N/A||1959|
|Mr. Geoffrey P. Gilmore||Sr. VP, Gen. Counsel & Corp. Sec.||701.53k||N/A||1966|
|Jason Butch||VP & Chief Accounting Officer||N/A||N/A||N/A|
|Ms. Tristen Herrstrom||Sr. VP of HR & Admin.||N/A||N/A||N/A|
|Matthew Riley||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Amy Welsh||VP of Marketing||N/A||N/A||N/A|
|Ms. Kimberly Whelan||VP of Sales & Market Access||N/A||N/A||N/A|
|Mr. Robert G. Conway||Sr. VP & Chief Supply Chain Officer||N/A||N/A||1957|
|Dr. Elizabeth Ijeoma Onyemelukwe Garner||Consultant||N/A||N/A||1968|
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Agile Therapeutics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 6.